Company: OSRH
Filing Date: 2025-05-28
Form Type: S-1
Source: 0001213900-25-048346
Chunk: 22

Company: OSR Holdings, Inc.
Filing Date: 2025-05-28
Form: S-1
Chunk 22
---
 all of which 
 may not be realized.                                                                              |

| ● | We incur substantial costs as a result of operating as a public company, and our management will                   
 devote substantial time to compliance with its public company responsibilities and corporate governance practices. |

| ● | The Company’ management team has limited experience managing and operating a U.S. public 
 company.                                                                                 |

| ● | If economic conditions in South Korea deteriorate, our current business and future growth could be 
 materially and adversely affected.                                                                 |

| ● | Our business includes subsidiaries that are developing oral immunotherapies for the treatment of                                
 cancer and design-augmented biologics. These companies have a limited operating history, and their programs are in early stages 
 of development. This may make it difficult to evaluate our prospects and likelihood of success.                                 |

| ● | We currently outsource, and intend to continue to outsource, much of our discovery, clinical development,                           
 and manufacturing functions to third-party providers or consultants. Outsourcing these functions has significant risks, and         
 our failure to manage these risks successfully could materially adversely affect our business, results of operations, and financial 
 condition.                                                                                                                          |

| ● | We face substantial competition, which may result in others discovering, developing, or commercializing                                    
 products before or more successfully than we do. If we are unable to obtain and maintain patent and other intellectual property protection 
 for our technology and product candidates or if the scope of the intellectual property protection obtained is not sufficiently broad,      
 we may not be able to compete effectively in our markets.                                                                                  |

The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not presently known to us, or that we currently deem to be immaterial, may also materially adversely affect our business, financial condition, results of operations, and future growth prospects. Corporate History and Information The Company was formed as a Delaware corporation on February 25, 2020, for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses. On February 14, 2023, we consummated our initial public offering (“ IPO”) of an aggregate of 6,000,000 units, at $10.00 per unit (“ Units”), generating gross proceeds of $60,000,000 before underwriting discounts and expenses. Simultaneously with the closing of our IPO, our sponsor, Bellevue Global Life Sciences Investors, LLC (“